Squarepoint Ops LLC Otonomy, Inc. Transaction History

Squarepoint Ops LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$1.69 - $2.31 $44,328 - $60,591	-26,230 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$1.22 - $2.2 $40,816 - $73,603	-33,456 Reduced 56.05%	26,230 $50,000
Q2 2021 Aug 16, 2021	SELL	$2.06 - $2.67 $292,484 - $379,094	-141,983 Reduced 70.4%	59,686 $133,000
Q1 2021 May 17, 2021	BUY	$2.49 - $6.23 $502,155 - $1.26 Million	201,669 New	201,669 $514,000
Q4 2020 Feb 16, 2021	SELL	$3.48 - $6.47 $117,074 - $217,663	-33,642 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$3.16 - $4.36 $106,308 - $146,679	33,642 New	33,642 $136,000
Q1 2019 May 15, 2019	SELL	$1.8 - $2.97 $21,209 - $34,995	-11,783 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$1.51 - $2.93 $22,049 - $42,783	-14,602 Reduced 55.34%	11,783 $22,000
Q3 2018 Nov 14, 2018	BUY	$2.6 - $3.95 $68,601 - $104,220	26,385 New	26,385 $73,000
Q1 2018 May 15, 2018	SELL	$4.05 - $6.1 $184,858 - $278,428	-45,644 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$2.8 - $5.55 $127,803 - $253,324	45,644	45,644 $253,000

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

Stay updated on Squarepoint Ops LLC with notifications on news.